Terkko Navigator / Lancet Respiratory Medicine

Correction to Lancet Respir Med 2021; published online Jan 8. https://doi.org/10.1016/S2213-2600(20)30552-X

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

New and old treatments for malignant mesothelioma: not just immunotherapy

Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial

Correction to Lancet Respir Med 2020; published online Dec 22. https://doi.org/10.1016/S2213-2600(20)30414-8

Use of point-of-care testing for respiratory viruses in hospital

Touch, and the absence of it

Untouched

Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia

Face masks in the post-COVID-19 era: a silver lining for the damaged tuberculosis public health response?

Each person is a world in COVID-19

Visionary insight

Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

The right place for IL-1 inhibition in COVID-19

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action

Realising the potential of SARS-CoV-2 vaccines—a long shot?

My COVID-19 dream: training enough health workers

An issue of trust—vaccinating Black patients against COVID-19

Trial participants' rights after authorisation of COVID-19 vaccines

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply

Assessing the importance of interleukin-6 in COVID-19

Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study

Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data

Misdiagnosis of sarcoidosis

Pandemic thoughts from a British junior doctor in Melbourne

Correction to Lancet Respir Med 2020; published online October 20. https://doi.org/10.1016/S2213-2600(20)30391-X

180 degree shift

COVID-19: the lessons learned amongst the losses

NICE guideline on long COVID

Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks

Improving family access to dying patients during the COVID-19 pandemic

Are women with asthma at increased risk for severe COVID-19?

Improving clinical management of COVID-19: the role of prediction models

Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

Implications of COVID-19 sequelae for health-care personnel

Sedation in mechanically ventilated patients with COVID-19

Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service

Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

A new year, but familiar challenges from COVID-19 in the USA

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

New variant of SARS-CoV-2 in UK causes surge of COVID-19

Correction to Lancet Respir Med 2021; 9: 69–84

Correction to Lancet Respir Med 2021; 9: 57–68

Overdiagnosis in lung cancer screening

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

Personalised medicine for asthma in a post-pandemic world